VALEANT RATING/EARNINGS UPDATE CFO Robert L. Rosiello bought 7,875 shares of the business’s stock in a transactionthat occurred on Friday, July 31st. The shares were purchased at an average cost of $254.28 per share, with a total value of $2,002,455.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
A number of other research firms have also recently commented on VRX. JPMorgan Chase & Co. reaffirmed a buy rating and set a $250.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Friday, June 26th. RBC Capital restated a buy rating on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, July 21st. Nomura began coverage on Valeant Pharmaceuticals Intl in a research report on Tuesday, September 29th. They set a buy rating and a $290.00 target price on the stock. Bank of America initiated coverage on Valeant Pharmaceuticals Intl in a research report on Wednesday, September 30th. They issued a buy rating and a $290.00 price objective on the stock. Finally, TD Securities reaffirmed a buy rating and issued a $300.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, September 23rd. Six research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $243.96.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 171.17 on Monday. Valeant Pharmaceuticals Intl has a one year low of $111.41 and a one year high of $263.81. The company’s 50-day moving average price is $213.07 and its 200 day moving average price is $223.74. The company has a market cap of $58.68 billion and a P/E ratio of 71.00.
Valeant Pharmaceuticals Intl (NYSE:VRX) last released its quarterly earnings data on Thursday, July 23rd. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.46 by $0.12. The business earned $2.73 million during the quarter, compared to analysts’ expectations of $2.04 million. During the same quarter last year, the business posted $1.91 EPS. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. On average, equities research analysts anticipate that Valeant Pharmaceuticals Intl will post $2.89 earnings per share for the current year.